Page 965 - Hematology_ Basic Principles and Practice ( PDFDrive )

848 Part VII Hematologic Malignancies

FUTURE DIRECTIONS 7. Bhaskar A, Raturi K, Dang S, et al: Current perspectives on the thera-
peutic aspects of chronic myelogenous leukemia. Expert Opin Ther Pat
The question of how initial genetic damage in hematopoietic stem 24:1117, 2014.
cell disorders causes a cascade of genetic events that leads to the 8. Schanz J, Tuchler H, Sole F, et al: New comprehensive cytogenetic scoring
development of malignancy is unresolved for many diseases. However, system for primary myelodysplastic syndromes (MDS) and oligoblastic
major advances have been made, and molecular unraveling of the acute myeloid leukemia after MDS derived from an international data-
consequence of the Philadelphia chromosome has led to the rationally base merge. J Clin Oncol 30:820, 2012.
designed imatinib treatment that has transformed CML from a fatal 9. Jonas B, Greenberg P: MDS prognostic scoring systems – Past, present,
disease into a chronic disorder compatible with normal life. Precise and future. Best Pract Res Clin Haematol 28:3, 2015.
molecular characterization of leukemic cells not only provides more 10. Ades L, Itzykson R, Fenaux P, et al: Myelodysplastic syndromes. Lancet
insight into the pathogenesis of disease but also allows patients to be 383:2239, 2014.
stratified as having high or low risk for recurrence and adverse 11. Martelli MP, Sportoletti P, Tiacci T, et al: Mutational landscape of AML
outcome. The ultimate goal is to translate this basic knowledge into with normal cytogenetics: biological and clinical implications. Blood Rev
increasingly better treatment options. Molecular diversity is currently 27:13, 2013.
the genetic hallmark of many leukemias, even within a single disease 12. Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hematopoiesis
entity such as AML or T-cell ALL. We are at the threshold of under- associated with adverse outcomes. N Engl J Med 371:2488, 2014.
standing other genetic events, common genetic pathways and intra- 13. Shlush LI, Zandi S, Mitchell A, et al: Identification of pre-leukaemic
tumor heterogeneity. Such an understanding is crucial to designing haematopoietic stem cells in acute leukaemia. Nature 506:328, 2014.
molecular interventions for specific abnormalities of genetic pathways 14. Grimwade D, Mrózek D: Diagnostic and prognostic value of cytogenet-
underlying hematologic malignancies. It is clear that the genetic revo- ics in acute myeloid leukemia. Hematol Oncol Clin North Am 25:1135,
lution has already changed the practice of clinical hematology. In the 2011.
future, molecular cytogenetics and cytogenomics, such as interphase- 15. De Braekeler E, Douet-Guilbert N, De Braekeler M: RARA fusion genes
directed locus-specific FISH technologies and aCGH + SNP, will be in acute promyelocytic leukemia. Expert Rev Hematol 7:347, 2014.
the key diagnostic, prognostic and follow-up tools during the routine 16. Meyer C, Hoffmann J, Burmeister T, et al: The MLL recombinome of
management of patients with hematologic malignancies. NGS acute leukemias in 2013. Leukemia 27:2165, 2013.
technology has enhanced the understanding of leukemic pathogenesis 17. Wong TN, Ramsingh G, Young AL, et al: Role of TP53 mutations in
and the origin and evolution of mutations and their temporal the origin and evolution of therapy – related acute myeloid leukaemia.
sequence, increasing the power for subclassifying leukemic entities Nature 518:552, 2014.
and allowing earlier diagnosis and more appropriate treatment for 18. Kayser S, Dohner K, Krauter J, et al: The impact of therapy-related acute
patients. Perhaps most dramatically, the complementary application myeloid leukemia (AML) on outcome in 2853 adult patients with newly
of these genetic methods has demonstrated intratumor heterogeneity. diagnosed AML. Blood 117:37, 2011.
Nonetheless, modern genomic studies provide a snapshot portrait of 19. Welch JS, Ley TJ, Link DC, et al: The origin and evolution of mutations
the total DNA within the tumor along with a mixture of normal and in acute myeloid leukemia. Cell 150:264, 2012.
abnormal cells. Systematic interrogation of subclonal genetic com- 20. Grossman G, Schnittger S, Kohlmann A, et al: A novel hierarchical
plexity and clonal architecture or phylogeny currently poses a techni- prognostic model of AML solely based on molecular mutations. Blood
cal challenge because three categories of mutational change; fusion 120:2963, 2012.
genes, CNVs, and SNPs, need to be identified in a single cell. In the 21. Bhojwani D, Yang J, Pui CH, et al: Biology of childhood acute lympho-
future, to construct a clonal evolutionary phylogeny, single cell analy- blastic leukemia. Pediatr Clin N Am 62:47, 2015.
sis using genetic profiling at diagnosis and relapse will provide detailed 22. Mullighan CG: The genomic landscape of acute lymphoblastic leukemia
subclonal genetic architecture. The challenge remains to translate the in children and young adults. Hematology Am Soc Hematol Educ Program
large leukemogenomics data into easily interpretable results accessible 2014:174, 2014.
to the hematologist for the purpose of more accurate and effective 23. Roberts KG, Mullighan CG: Genomics in acute lymphoblastic leukae-
therapies. mia: insights and treatment implications. Nat Rev Clin Oncol 12:344,
2015.
24. Harrison CJ: Blood Spotlight on iAMP21 acute lymphoblastic leukemia
REFERENCES (ALL); a high-risk pediatric disease. Blood 125:1383, 2015.
25. Olsson L, Johansson B: Ikaros and leukaemia. Br J Haematol 169:479,
1. Alpar D, Wren D, Ermini L, et al: Clonal origins of ETV6-RUNX1+ 2015.
acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia 26. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and
29:839, 2015. survival in chronic lymphocytic leukemia. N Engl J Med 343:1910, 2000.
2. Greaves M: Darwin and evolutionary tales in leukemia. Hematology 27. Bolli N, Avet-Loiseau H, Wedge DC, et al: Heterogeneity of genomic
3–12, 2009. evolution and mutational profiles in multiple myeloma. Nat Commun
3. Yang L, Rau R, Goodell MA, et al: DNMT3A in haematological malig- 5:2997, 2014.
nancies. Nat Rev 15:152, 2015. 28. Correia C, Schneider PA, Dai H, et al: BCL2 mutations are associated
4. Nowell PC, Hungerford DA: A minute chromosome in human chronic with increased risk of transformation and shortened survival in follicular
granulocytic leukemia. Science 132:1497, 1960. lymphoma. Blood 125:658, 2015.
5. Rowley JD: A new consistent chromosomal abnormality in chronic 29. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell
myelogenous leukemia identified by quinicrine fluorescence and Giemsa leukemia. N Engl J Med 364:2305, 2011.
staining. Nature 243:290, 1973. 30. Starza RL, Borga C, Barba G, et al: Genetic profile of T-cell acute
6. Martin PJ, Najfeld V, Hansen JA, et al: Involvement of the B-lymphoid lymphoblastic leukemias with MYC translocations. Blood 124:3577,
system in chronic myelogenous leukemia. Nature 287:49, 1980. 2014.